Want to see ZVSA full AI Analyst Report?
Top Page
ZyVersa Therapeutics
(OTC:ZVSA)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.08
▼(-24.00% Downside)
Action:Reiterated
Date:10/02/26
The score is driven primarily by weak financial performance (no revenue, large losses, heavy cash burn, and a stressed balance sheet with negative equity and higher debt). Technicals are also bearish with the stock trading below key moving averages and negative MACD, while valuation offers limited support due to ongoing losses and no dividend. Corporate events add downside risk via the move to OTC Pink and strategic-alternatives/cost-cutting actions.
Positive Factors
Renal and inflammatory disease focus
A focused pipeline addressing renal and inflammatory diseases gives ZyVersa a defined therapeutic strategy and potential exposure to substantial unmet medical needs. Continued concentration can help direct scarce resources toward indications where clinical progress could create durable asset value.
Negative Factors
No revenue base
Zero revenue across the reported periods confirms ZyVersa remains pre-commercial and has no sales base to offset research, development, or corporate spending. Until a candidate reaches commercialization, ongoing operations depend on financing and successful clinical execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Renal and inflammatory disease focus
A focused pipeline addressing renal and inflammatory diseases gives ZyVersa a defined therapeutic strategy and potential exposure to substantial unmet medical needs. Continued concentration can help direct scarce resources toward indications where clinical progress could create durable asset value.
Read all positive factors
ZyVersa Therapeutics (ZVSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$647.67K
Dividend YieldN/A
Average Volume (3M)5.23K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue GrowthN/A
EPS Growth57.26%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.32
Shares Outstanding8,095,921
10 Day Avg. Volume6,778
30 Day Avg. Volume5,226
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-156.26
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-65.8
Revenue Forecast (FY)N/A
ZyVersa Therapeutics Business Overview & Revenue Model
Company Description
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a ch...
ZyVersa Therapeutics Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
5
Very Negative
Cash Flow
6
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -6.93K | -10.40K | -10.40K | -10.40K |
| EBITDA | -24.69M | -25.29M | -9.14B | -107.74M | -14.43M | -7.25M |
| Net Income | -24.49M | -24.95M | -9.41B | -98.30M | -14.05M | -8.08M |
Balance Sheet | ||||||
| Total Assets | 742.22M | 347.90M | 20.60M | 22.11M | 118.51M | 1.13M |
| Cash, Cash Equivalents and Short-Term Investments | 302.66M | 101.78M | 1.53M | 3.14M | 5.90M | 328.58K |
| Total Debt | 1.20B | 0.00 | 0.00 | 8.66K | 108.76K | 9.15M |
| Total Liabilities | 14.87B | 12.73B | 12.08M | 11.04M | 18.51M | 13.63M |
| Stockholders Equity | -14.12M | -12.39B | 8.52M | 11.07M | 99.99M | -12.50M |
Cash Flow | ||||||
| Free Cash Flow | -2.62B | -5.11M | -7.56M | -8.72M | -1.49M | -5.08M |
| Operating Cash Flow | -2.62B | -5.11M | -7.56M | -8.72M | -4.89M | -5.08M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 2.83B | 3.69M | 5.95M | 5.96M | 1.87M | 5.23M |
ZyVersa Therapeutics Technical Analysis
Negative
0.10
Price Trends
0.10
Negative
0.13
Negative
0.17
Negative
Market Momentum
>-0.01
Positive
33.14
Neutral
4.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZVSA, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.17, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 33.14 is Neutral, neither overbought nor oversold. The STOCH value of 4.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZVSA.
ZyVersa Therapeutics Risk Analysis
ZyVersa Therapeutics disclosed 86 risk factors in its most recent earnings report. ZyVersa Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Following a reverse stock split, the resulting market price of our Common Stock may not attract new investors, including institutional investors, and may not satisfy the investing requirements of those investors. Consequently, the trading liquidity of our Common Stock may not improve. Q4, 2023
2.
Our reverse stock split may decrease the liquidity of the shares of our Common Stock. Q4, 2023
3.
Unless our Common Stock continues to be listed on a national securities exchange it will become subject to the so-called "penny stock" rules that impose restrictive sales practice requirements. Q4, 2023
ZyVersa Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
ZVSA
ZyVersa Therapeutics
0.08
-0.08
-50.00%
SCNI
Scinai Immunotherapeutics
1.33
-12.22
-90.18%
ADTX
Aditxt
0.04
-16,736.52
-100.00%
CERO
CERo Therapeutics Holdings
0.01
-5.38
-99.81%
PBM
Psyence Biomedical
5.16
-15.84
-75.43%
CDT
CDT Equity
0.99
-41,489.01
-100.00%
ZyVersa Therapeutics Corporate Events
Delistings and Listing Changes
ZyVersa Therapeutics Transitions to OTC Pink Market
Negative
Jul 17, 2026
Effective July 16, 2026, ZyVersa Therapeutics, Inc. ceased trading on the OTCQB Venture Market and began trading on the OTC Pink Limited Market. The move to the OTC Pink tier represents a change in the company’s trading status that may affec...
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
ZyVersa Therapeutics Pursues Strategic Alternatives, Cuts Costs
Negative
Jul 10, 2026
ZyVersa Therapeutics’ board and management have begun implementing and evaluating cost-cutting measures to preserve cash while the company seeks to raise capital. Chief Executive Officer Stephen Glover and Chief Financial Officer Peter Wolfe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.